Clinical Trials Browser

Interventional × Breast Neoplasms × AZD 6244 × Clear all

NCT03162627 2026-04-15

Selumetinib and Olaparib in Solid Tumors

Phase 1 Active not recruiting

Breast Neoplasms

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

Phase 2 Active not recruiting

Breast Neoplasms

NCT00780676 2020-09-03

Personalized Treatment Selection for Metastatic Breast Cancer

Phase 2 Terminated

97 enrolled 7 charts

Breast Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT01160718 2019-05-15

Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy

Phase 2 Completed

Breast Neoplasms

NCT01313039 2017-02-07

Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer

Phase EARLY_PHASE1 Completed

4 enrolled 5 charts

Breast Neoplasms